Picard Medical, Inc. (PMI)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Picard Medical, Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 4 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 5.10 $ — 38% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
3/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% 9.3%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 9.3%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight –
- Max. EBIT decline < 50% –
- Return on equity > 15% -1,013.1%
- ROCE > 15% -332.2%
- Expected return > 10% 6.5%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 6.3% failed
- More than 10% revenue growth is expected for the coming year 7.3% failed
- Share count grows by less than 3% a year 0.8% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -304.8% failed
- Gross margin at 40% or higher and without meaningful erosion 4.1% failed
- Goodwill from acquisitions does not grow faster than revenue 2.7% passed
- Net debt below twice EBITDA 0 m net cash passed
- Operating cash flow covers the profits of the last three years 25 m failed
- Return on capital at 15% or higher, or up versus two years ago -332.2% failed
- Insiders hold at least 10% or are net buyers 53.0% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -8.50 | -8.50 – -8.50 | 6 | – | 1 |
| 12/31/2027 | -4.50 | -4.50 – -4.50 | 6 | – | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.03 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.09 | – | 1 | 1.20 | -1,057.20 | -3 | -3 |
| 2025: Q1 | -0.06 | – | 1 | -68.70 | -896.90 | -2 | -2 |
| 2025: Q2 | -0.08 | – | 2 | 207.10 | -352.90 | -3 | -3 |
| 2025: Q3 | -0.11 | – | 1 | 34.70 | -878.30 | -7 | -7 |
| 2025: Q4 | -0.05 | – | 1 | 20.70 | -425.10 | -4 | -4 |
| 2026: Q1 | -0.08 | – | 1 | 85.50 | -662.30 | -4 | -4 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2022 | 4 | -11 | -11 | -0.16 | -11 | 11 | 15 |
| 2023 | 5 | -16 | -16 | -0.22 | -11 | -4 | 11 |
| 2024 | 4 | -14 | -21 | -0.29 | -12 | -24 | 12 |
| 2025 | 5 | -13 | -27 | -0.37 | -16 | 4 | 23 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Picard Medical, Inc. befasst sich zusammen mit seinen Tochtergesellschaften mit Entwurf, Herstellung, Produktion, Lieferung, Vermarktung und Verkauf von Medizinprodukten.
| Employees | 75 |
|---|---|
| Headquarters | Tucson, AZ |
| Address | 1992 East Silverlake Road, 85713 Tucson, United States |
| Phone | 520 545 1234 |
| Website | picardmedical.com |
| IPO Date | 29. Aug 2025 |
| ISIN | US71953R1086 |
| Stock Split | 1:50 on 08/03/2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Yuncai Fang Ph.D. | Interim CEO & Chairman of the Board | 1966 |
| Matthew Schuster | Chief Operating Officer | 1981 |
| Georgina Smith | Chief Accounting Officer | 1972 |
| Frank Tinker Ph.D. | Chief Technology Officer of SynCardia Systems, LLC | 1956 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 24. Apr 2026 | Michael Patrick O'Shea | Insider | Buy | 4,463 | 0.00 | – |
| 24. Apr 2026 | Piers Godfrey Harrison | Insider | Buy | 4,463 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.